Age-related macular degeneration

Czech version

Authors: Alexandr Stěpanov
Authors‘ workplace: Oční klinika LF UK a FN Hradec Králové
Published in: Geriatrie a Gerontologie 2021, 10, č. 2: 87-91
Category: Review Article

Overview

Age-related macular degeneration (AMD) is the most common cause of vision loss in people over the age of 65 in developed countries. In most patients, a „dry“ form of AMD is noted, which gradually progresses. Choroidal nonvascular membrane is the main sign of „wet“ form of AMD which is present in 10 % of patients approximately. AMD develops as a result of an interaction between genetic and lifestyle factors of patients. The treatment of the choice of the wet form of AMD is intravitreal anti-VEGF injections, in the case of the dry form of AMD we can choose antioxidants, preparations with lutein and haemorheopheresis. An essential prerequisite for successful treatment is early diagnosis and especially early initiation of the treatment.

Keywords:

age-related macular degeneration – lutein – rheohaemapheresis – ranibizumab – aflibercept – brolucizumab

Sources

Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004; 44: 17–39.
Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study: I. Outline and major prevalence findings. Am J Epidemiol 1977; 106(1): 17–32.
Augood CA, Vingerling JR, de Jong PTVM, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006; 124(4): 529–535.
Alberti WE, Richard G, Sagerman RH. Age-Related Macular Degeneration: Current Treatment Concepts. 1st ed. Berlin: Springer-Verlag Berlin Heidelberg New York 2001; 207.
Klein R, Klein BEK, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the Multi-ethnic Study of Atherosclerosis. Ophthalmology 2006; 113(3): 373–380.
Delcourt C, Diaz JL, Ponton-Sanchez A, et al. Smoking and age-related macular degeneration: the POLA Study. Arch Ophthalmol 1998; 116(8): 1031–1035.
Zweifel SA, Spaide RF, Curcio CA, et al. Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology 2010; 117(2): 303–312.
Age-related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta karotene and zinc for age-related macular degeneration and vision loss. AREDS Report 8. Arch Ophthalmol 2001; 119: 1417–1436.
Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic agerelated macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004; 75 (4): 216–230.
Klingel R, Fassbender C, Fassbender T, et al. Clinical studies to implement rheopheresis for age-related macular degeneration guided by evidence-basedmedicine. Transf Apher Sci 2003; 29: 71–84.
Rencová E, Bláha M, Studnička J, et al. Preservation of the photoreceptor inner/outer segment junction in dry age-related macular degeneration treated by rheohemapheresis. J Ophthalmol 2015; 359747.
Brunner R, Widder RA, Walter P, et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration: a randomized trial. Retina 2000; 20(5): 483–491.
Narayanan R, Kuppermann BD, Jones C, et al. Ranibizumab. Nat Rev Drug Discov 2006; 5(10): 815–816.
Studnička J. Ranibizumab (Lucentis) v léčbě věkem podmíněné makulární degenerace. Čes a Slov Oftal 2009; 65(3): 107–111.
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006; 355(14): 1432–1444.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419–1431.
Spaide R. Ranibizumab according to need: a treatment for agerelated macular degeneration. Am J Ophthalmol 2007; 143(4): 679–680.
Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144(4): 627–637.
Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov 2012; 11(4): 269–270.
Ohji M, Takahashi K, Okada AA, et al. ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : a randomized controlled trial. Adv Ther 2020; 37(3): 1173–1187.
Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antipody fragment VEGF inhibitor rth258 for neovascular age-related macular degeneration: A randomized controlled study. Ophthalmology 2016; 123(5): 1080–1089.
Tietz J, Schmid G, Konrad J, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders. Invest Ophthalmol Vis Sci 2015; 56: 1501.
Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology 2017; 124(9): 1296–1304.
Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology 2017; 124(9): 1296–1304.
Straňák Z, Kousal B, Ardan T, Veith M. Inovativní postupy v léčbě sítnicových onemocnění. Čes a Slov Oftal 2019; 75 (6): 287–295.
Nanduri D, Fine I, Horsager A, et al. Frequency and amplitude modulation have different effects on the percepts elicited by retinal stimulation. Invest Ophthalmol Vis Sci 2012; 53: 205–214.
Lorach H, Goetz G, Smith R, et al. Photovoltaic restoration of sight with high visual acuity. Nat Med 2015; 21: 476–482.
Scharioth GB. New Add-on Intraocular lens for patients with age-related macular degeneration. J Cataract Refract Surg 2015; 41: 1559–1563.
Nekolová J, Kremláček J, Kuba M, et al. Možnosti zlepšení zrakových funkcí u pacientů se stabilní makulopatií-pilotní výsledky nové studie. Čes a Slov Oftal 2019; 75(3): 130–135.